NCT00374075View on ClinicalTrials.gov

Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

February 28, 2006

Conditions
Spinal Muscular Atrophy
Interventions
DRUG

Valproic Acid

Trial Locations (1)

84132

University of Utah/Primary Children's Medical Center, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

Families of Spinal Muscular Atrophy

OTHER

collaborator

Leadiant Biosciences, Inc.

INDUSTRY

collaborator

Abbott

INDUSTRY

lead

University of Utah

OTHER

NCT00374075 - Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy | Biotech Hunter | Biotech Hunter